HPTN 057
A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir
Disoproxil Fumarate in HIV-1 Infected Pregnant Women and their Infants
|
Study Documents
The HPTN 057 study team has made the
following study documents available. New documents will be posted
here as they become available.
HPTN 057 Protocol
HPTN 057 Study Specific
Procedures Manual
-
HPTN 057 SSP
Manual v 4.0 Zip File (in revision)
-
Change Log (Word)
(PDF)
(in revision)
-
Front Matter
-
Table of Contents (Word)
(PDF)
(in revision)
-
Section 1
Introduction (Word)
(PDF)
(18 Feb 2010)
-
Section 2 Protocol (Word) (PDF)
(18 Feb 2010)
-
Section 3
Documentation Requirements (Word)
(PDF)
(18 Feb 2010
-
Section 4 Participant
Accrual (Word)
(PDF)
(18 Feb 2010
-
Section 5 Participant
Follow-up (Word)
(PDF)
(18 Feb 2010)
-
Section 6 Visit
Checklists (Word)
(PDF)
(18 Feb 2010)
-
Section 7 Retention (Word)
(PDF)
(18 Feb 2010)
-
Section 8 Study
Product Considerations (Word)
((in revision)
-
Section 9 Clinical
and Counseling Procedures (Word)
(PDF)
(18 Feb 2010)
-
Section 10 Laboratory
Procedures (Word)
(PDF)
(11 Mar 2010)
-
Section 11 Adverse
Event Reporting and Safety Monitoring (Word)
(PDF)
(in revision)
-
Section 12 DataFax (PDF)
(18 Feb 2010)
HPTN 057 Case Report Forms
Please contact
Lynda Emel at SCHARP to obtain the latest version of the HPTN 057
CRFs
HPTN 057 Study Implementation Documents and Resources
HPTN 057 Site-Specific Study Operating Procedures (SOPs)
HPTN 057 Safety Monitoring and Adverse Event Reporting
HPTN 057 Resources
|